140 related articles for article (PubMed ID: 38900699)
1. Successful Distribution of Tecovirimat During the Peak of the Mpox Outbreak - Los Angeles County, June 2022-January 2023.
O'Neil MJ; Archer R; Danza P; Fisher R; Bagwell DA; Younis I; Kulkarni S; Rubin Z; Kim M; Balter S; Terashita D; Kim J; Singhal R; Hancz D; Gausche-Hill M; Shah NK
MMWR Morb Mortal Wkly Rep; 2024 Jun; 73(24):546-550. PubMed ID: 38900699
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Complicated Mpox Cases Unresponsive to Oral Tecovirimat in Los Angeles County, 2022.
Karan A; Shah N; Garrigues JM; Alarcόn J; Hemarajata P; Finn LE; Poortinga K; Danza P; Kulkarni S; Kim M; Terashita D; Green NM; Balter S
J Infect Dis; 2024 Mar; 229(Supplement_2):S249-S254. PubMed ID: 37995310
[TBL] [Abstract][Full Text] [Related]
3. Mpox Outbreak - Los Angeles County, California, May 4-August 17, 2023.
Leonard CM; Poortinga K; Nguyen E; Karan A; Kulkarni S; Cohen R; Garrigues JM; Marutani AN; Green NM; Kim AA; Sey K; Pérez MJ
MMWR Morb Mortal Wkly Rep; 2024 Jan; 73(2):44-48. PubMed ID: 38236779
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
[TBL] [Abstract][Full Text] [Related]
5. Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
Russo AT; Grosenbach DW; Honeychurch KM; Long PG; Hruby DE
Expert Rev Anti Infect Ther; 2023 Mar; 21(3):235-242. PubMed ID: 36728515
[TBL] [Abstract][Full Text] [Related]
6. Early Tecovirimat Treatment for Mpox Disease Among People With HIV.
Aldred B; Lyles RH; Scott JY; Gromer DJ; Aldredge A; Workowski KA; Wiley Z; Titanji BK; Szabo B; Sheth AN; Rebolledo PA; Nguyen ML; Marconi VC; Kelley CF; Kandiah S; Kalapila A; Jacob JT; Hall B; Colasanti JA; Cartwright EJ; Cantos VD
JAMA Intern Med; 2024 Mar; 184(3):275-279. PubMed ID: 38190312
[TBL] [Abstract][Full Text] [Related]
7. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y;
MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794
[TBL] [Abstract][Full Text] [Related]
8. Expanded Access Programme for the use of tecovirimat for the treatment of monkeypox infection: A study protocol for an Expanded Access Programme.
Bourner J; Redji Mbrenga FD; Malaka CN; Dunning J; Rojek A; Fandema E; Horby P; Boum Y; Nakouné E; Olliaro P
PLoS One; 2024; 19(5):e0278957. PubMed ID: 38722986
[TBL] [Abstract][Full Text] [Related]
9. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
[TBL] [Abstract][Full Text] [Related]
10. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study.
McLean J; Stoeckle K; Huang S; Berardi J; Gray B; Glesby MJ; Zucker J
Ann Intern Med; 2023 May; 176(5):642-648. PubMed ID: 37126820
[TBL] [Abstract][Full Text] [Related]
11. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection.
Nguyen BT; Marc A; Suñer C; Marks M; Ubals M; Hernández-Rodríguez Á; Melendez MÁ; ; Hruby DE; Russo AT; Mentré F; Mitjà O; Grosenbach DW; Guedj J
PLoS Biol; 2023 Dec; 21(12):e3002249. PubMed ID: 38127878
[TBL] [Abstract][Full Text] [Related]
12. Mpox in Children: 3 Cases.
Frantzis I; Ungar SP; Soma VL; Knutsen D; Mazo D; Zucker J
Pediatrics; 2024 Jan; 153(2):. PubMed ID: 38239109
[TBL] [Abstract][Full Text] [Related]
13. Mpox in the New York metropolitan area, Summer 2022.
Gnanaprakasam R; Keller M; Glassman R; El-Khoury MY; Chen DS; Feola N; Feldman J; Chaturvedi V
J Med Virol; 2023 Apr; 95(4):e28699. PubMed ID: 36951318
[TBL] [Abstract][Full Text] [Related]
14. Tecovirimat for the treatment of severe Mpox in Germany.
Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
[TBL] [Abstract][Full Text] [Related]
15. Treatment and Vaccination for Smallpox and Monkeypox.
Saalbach KP
Adv Exp Med Biol; 2024; 1451():301-316. PubMed ID: 38801586
[TBL] [Abstract][Full Text] [Related]
16. Implementation and early outcomes of a telehealth visit model to deliver tecovirimat for mpox infection in New York City.
Chan J; DiTullio DJ; Pagan Pirallo P; Foote M; Knutsen D; Kottkamp AC; McPherson TD; Mukherjee V; Pitts R; Wallach A; Wong M; Mazo D; Mgbako O
J Telemed Telecare; 2023 Aug; ():1357633X231194796. PubMed ID: 37632124
[TBL] [Abstract][Full Text] [Related]
17. Identification of Tecovirimat Resistance-Associated Mutations in Human Monkeypox Virus - Los Angeles County.
Garrigues JM; Hemarajata P; Karan A; Shah NK; Alarcón J; Marutani AN; Finn L; Smith TG; Gigante CM; Davidson W; Wynn NT; Hutson CL; Kim M; Terashita D; Balter SE; Green NM
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0056823. PubMed ID: 37338408
[No Abstract] [Full Text] [Related]
18. A Case of Neonatal Monkeypox Treated With Oral Tecovirimat.
Castejon-Ramirez S; Pennington J; Beene H; Hysmith N; Ost S
Pediatrics; 2024 Jan; 153(1):. PubMed ID: 38148743
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
Akiyama Y; Morioka S; Tsuzuki S; Yoshikawa T; Yamato M; Nakamura H; Shimojima M; Takakusaki M; Saito S; Takahashi K; Sanada M; Komatsubara M; Takebuchi K; Yamaguchi E; Suzuki T; Shimokawa K; Kurosu T; Kawahara M; Oishi K; Ebihara H; Ohmagari N
J Infect Chemother; 2024 Jun; 30(6):488-493. PubMed ID: 38042298
[TBL] [Abstract][Full Text] [Related]
20. Therapeutics for treating mpox in humans.
Fox T; Gould S; Princy N; Rowland T; Lutje V; Kuehn R
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD015769. PubMed ID: 36916727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
